Key Highlights
- 8.65% is the indicated pre-market decline for Ping An Biomedical Co., Ltd. (NASDAQ:PASW) on November 18, 2026, to USD 1.32, against a calculated prior close of USD 1.4450 and a calculated move of -USD 0.1250.
- 9.6 million is the RMB Revenue for the six months ended March 31, 2026, down 47% from RMB 18.23 million, as operations swung to a profit of RMB 0.5 million from a loss of RMB 3.6 million.
- 4.8 million is the RMB Net Income for the period, lifted by RMB 11.8 million of non-operating gains, including a RMB 6.1 million Credit loss Reversal and a RMB 5.7 million Equity Revaluation gain.
- 23 is the November date in 2026 by which Ping An Biomedical Co., Ltd. (NASDAQ:PASW) is cited as having to regain compliance with the Nasdaq minimum bid price rule, after receiving a deficiency letter on November 28, 2025.
What Moved Ping An Biomedical Co., Ltd. (NASDAQ:PASW) in Pre-Market Trading on November 18, 2026 (-USD 0.1250, -8.65%)
Ping An Biomedical Co., Ltd. (NASDAQ:PASW) is indicated at USD 1.32 in pre-market trading on Wednesday, November 18, 2026, a move of -8.65% before the 9:30 a.m. ET open. The calculated prior close, the November 17, 2026 regular-session close, is USD 1.4450 (USD 1.32 divided by 0.9135), so the calculated USD move is -USD 0.1250. Published market data on Market Value and share count conflicted across sources, so neither is used here.
The Rationale: No Fresh Catalyst, With a Nasdaq Bid Price Deadline Approaching for Ping An Biomedical Co., Ltd. (NASDAQ:PASW)
No company release or filing dated November 18, 2026 was identified in published coverage to explain the move. As general context, low-priced shares of small listed companies often move on thin Liquidity and sentiment around listing deadlines. The company announced receipt of a Nasdaq minimum bid price deficiency letter on November 28, 2025, and published coverage cites an extended compliance date of November 23, 2026, with a Reverse Stock Split possible as a remedy. In its results for the six months ended March 31, 2026, revenue fell 47% to RMB 9.6 million, yet net income was RMB 4.8 million because of RMB 11.8 million in non-operating gains.
Valuation, Liquidity and Risks for Ping An Biomedical Co., Ltd. (NASDAQ:PASW)
Core operations are in textile and garment trading, which is contracting as the company shifts toward an equity Investment model. Cash and bank balances were RMB 35.9 million, of which RMB 29.1 million, or 81%, was restricted, and the equity investment portfolio was valued at RMB 41.2 million. Concentration is high, with the top three customers generating 70% of revenue and one supplier accounting for 54% of purchases. Profit rested on non-cash gains rather than operations. Listing compliance, possible dilution or a reverse split, and valuation swings in the investment portfolio are the main risks.
Where Things Stand
Ping An Biomedical Co., Ltd. (NASDAQ:PASW) is indicated at USD 1.32 in pre-market trading on November 18, 2026, down 8.65% from a calculated prior close of USD 1.4450, a calculated decline of USD 0.1250. No catalyst dated today was identified in published coverage. The latest results show revenue down 47% to RMB 9.6 million, net income of RMB 4.8 million helped by RMB 11.8 million of non-operating gains, and restricted cash of RMB 29.1 million out of RMB 35.9 million, with a bid compliance date of November 23, 2026. This article is informational and is not investment advice.




Please wait processing your request...